Drugs / Oxaliplatin
Oxaliplatin
also known as
Eloxatin · oxaliplatine · OXA · l-OHP · Oxaliplatin (Eloxatin) · OXAL · SR96669 · NSC 266046 · +22 more
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (4) | US (FDA) | ELOXATIN | — | 2004-01-09 – 2008-05-21 | fda.gov ↗ |
| Approved | US (FDA) | ELOXATIN | — | 2002-08-09 | fda.gov ↗ |
Trials 1,746 · started per year
today
US approved 2002
5
19
29
10
18
40
77
66
68
55
56
44
48
57
57
50
45
59
53
56
73
62
79
85
98
98
118
113
101
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 010 trials | ||||||
| Phase 0 | NCT07254091 | Jan 2026 → Jan 2027 expected | malignant pancreatic neoplasm | Northwell Health | Recruiting | No outcome recorded |
| Phase 0 | NCT07356466 | May 2025 → Apr 2027 expected | gastric cancer | Fujian Medical University | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT05007587 | Jul 2021 → Jun 2022 | hepatocellular carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT03970252 | Jul 2019 → May 2024 | pancreatic ductal adenocarcinoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT03515941 | Jun 2018 → Mar 2020 | digestive system cancer | Tannaz Armaghany | Terminated | No outcome recorded |
| Phase 0 | NCT03600623 | Sep 2017 → Jul 2020 | malignant pancreatic neoplasm, pancreatic exocrine neoplasm | University of Alabama at Birmingham | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT02896907 | Oct 2016 → Mar 2018 | pancreatic adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 0 | NCT02077998 | May 2015 | female breast carcinoma | University of California, Davis | Completed | No outcome recorded |
| Phase 0 | NCT01992705 | Mar 2014 → Sep 2018 | pancreatic exocrine neoplasm | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 0 | NCT01821612 | May 2013 → Nov 2014 | pancreatic acinar cell carcinoma, pancreatic ductal adenocarcinoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 1151 trials | ||||||
| Phase 1 | NCT07829185 | Dec 2026 → Dec 2029 expected | pancreatic ductal adenocarcinoma | University of Oklahoma | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07859085 | Oct 2026 → Mar 2029 expected | colorectal neoplasm, pancreatic ductal adenocarcinoma | Genentech, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07060014 | Sep 2026 → Sep 2028 expected | appendix cancer, small intestine cancer | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT07824934 | Sep 2026 → May 2028 expected | cancer | Sunshine Lake Pharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07649655 | Jul 2026 → Mar 2028 expected | colorectal cancer | Shanghai EpimAb Biotherapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07453875 | May 2026 → Nov 2027 expected | peritoneal carcinomatosis | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07477743 | Mar 2026 → Dec 2027 expected | — | HC Biopharma Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05296005 | Dec 2025 | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Ohio State University Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT07030283 | Dec 2025 → Jul 2028 expected | pancreatic ductal adenocarcinoma | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1 | NCT07059299 | Dec 2025 → Aug 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting | No outcome recorded |
| Show all 151 trials opens the full record — a long page | ||||||
| Phase 1/2142 trials · 2 met primary · 5 missed | ||||||
| Phase 1/2 | NCT07791758 | Sep 2026 → Sep 2030 expected | colorectal carcinoma | Nanjing Leads Biolabs Co.,Ltd | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07653685 | Sep 2026 → Jun 2027 expected | colorectal cancer | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07863869 | Sep 2026 → May 2029 expected | colorectal cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07805551 | Aug 2026 → Aug 2030 expected | colorectal cancer | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07522411 | Apr 2026 → Dec 2027 expected | hepatocellular carcinoma | BinYong Liang | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07453394 | Apr 2026 → Apr 2027 expected | endometrial cancer, gastric cancer, non-small cell lung carcinoma, ovarian cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07595172 | Apr 2026 → Aug 2028 expected | pancreatic ductal adenocarcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07327229 | Feb 2026 → Sep 2027 expected | gastroesophageal adenocarcinoma | Antengene Biologics Limited | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07282184 | Oct 2025 → Jun 2027 expected | hepatocellular carcinoma | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07256782 | Oct 2025 → Oct 2026 expected | neoplastic disease or syndrome | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Show all 142 trials opens the full record — a long page | ||||||
| Phase 21,088 trials · 19 met primary · 27 missed | ||||||
| Phase 2 | NCT07828873 | Nov 2026 → Sep 2029 expected | gastroesophageal adenocarcinoma | The First Affiliated Hospital of Zhengzhou University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07797244 | Oct 2026 → Apr 2029 expected | colorectal cancer | Dai, Guanghai | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07711483 | Oct 2026 → Oct 2028 expected | B-cell non-Hodgkin lymphoma, large B-cell lymphoma | Massachusetts General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07779694 | Oct 2026 → Dec 2028 expected | rectal carcinoma | Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07854600 | Oct 2026 → Oct 2028 expected | biliary tract cancer | Haitao Zhao, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT07802418 | Oct 2026 → Jun 2031 expected | malignant pancreatic neoplasm | Herlev Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07814417 | Oct 2026 → Nov 2028 expected | colorectal neoplasm | Eli Lilly and Company | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07802288 | Sep 2026 → Apr 2029 expected | gastroesophageal adenocarcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07847710 | Sep 2026 → Mar 2028 expected | intrahepatic cholangiocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07815288 | Sep 2026 → Dec 2029 expected | colorectal adenocarcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Show all 1,088 trials opens the full record — a long page | ||||||
| Phase 2/349 trials · 6 met primary · 8 missed | ||||||
| Phase 2/3 | NCT07866313 | Jun 2026 → Aug 2028 expected | colorectal cancer | Changhai Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07490262 | Mar 2026 → Dec 2027 expected | hepatocellular carcinoma | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06904170 | Nov 2025 → Sep 2029 expected | hepatocellular carcinoma | UNICANCER | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06841679 | Aug 2025 → Sep 2030 expected | gastroesophageal adenocarcinoma | Beijing Biostar Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06028737 | Mar 2025 → Apr 2027 expected | gastric adenocarcinoma, gastroesophageal cancer, gastroesophageal junction adenocarcinoma | Ukrainian Society of Clinical Oncology | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06758830 | Jan 2025 → Dec 2029 expected | rectal cancer | National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06441565 | May 2024 → Dec 2025 overdue | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06279130 | Jan 2024 → Jan 2029 expected | — | The Netherlands Cancer Institute | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05976568 | Sep 2023 → Sep 2027 expected | hepatocellular carcinoma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05980481 | Aug 2023 → Jul 2025 overdue | gastric cancer | RemeGen Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05610163 | Dec 2022 → Jul 2030 expected | rectum adenocarcinoma | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05325528 | Apr 2022 → Aug 2025 | — | Zhejiang University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05139017 | Jan 2022 → Sep 2027 expected | diffuse large B-cell lymphoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05171166 | Dec 2021 → Oct 2025 | hepatocellular carcinoma | Peking University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT04669496 | Jan 2021 → Apr 2025 overdue | intrahepatic cholangiocarcinoma | Shanghai Zhongshan Hospital | Active not recruiting | Met primary |
| Phase 2/3 | NCT04677673 | Jan 2021 → Jan 2022 overdue | chemotherapy-induced toxicity, gastric cancer | BIRENDRA KUMAR SAH | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT04068103 | Dec 2019 → Jun 2023 overdue | colon adenocarcinoma | NRG Oncology | Active not recruiting | Missed primary |
| Phase 2/3 | NCT04060472 | Aug 2019 → Apr 2021 | hepatobiliary neoplasm | Dong Wang | Unknown | No outcome recorded |
| Phase 2/3 | NCT04393584 | Jan 2019 → Jan 2024 | gastric neoplasm | Blokhin's Russian Cancer Research Center | Unknown | No outcome recorded |
| Phase 2/3 | NCT03691454 | Jun 2018 → Sep 2026 overdue | gastric adenocarcinoma | Peking University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03957733 | Nov 2017 → May 2022 | rectal cancer | King Abdullah Medical City | Unknown | No outcome recorded |
| Phase 2/3 | NCT02758951 | Jun 2017 → Oct 2024 overdue | colorectal adenocarcinoma, peritoneal carcinoma, peritoneal carcinomatosis | Koen Rovers | Active not recruiting | Missed primary |
| Phase 2/3 | NCT02919787 | Sep 2016 → Dec 2022 overdue | pancreatic ductal adenocarcinoma | Oslo University Hospital | Active not recruiting | Missed primary |
| Phase 2/3 | NCT02591030 | Dec 2015 → Jun 2018 | bile duct cancer | University Hospital of Saint-Etienne | Completed | Missed primary |
| Phase 2/3 | NCT02585479 | Oct 2015 → Oct 2017 | hepatocellular carcinoma | Guangxi Medical University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02584556 | Oct 2015 → Oct 2017 | hepatocellular carcinoma | Guangxi Medical University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02534337 | Sep 2015 → Sep 2017 | hepatocellular carcinoma | Guangxi Medical University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02529774 | Sep 2015 → Sep 2020 | metastasis from malignant tumor of colon | Ye Xu | Unknown | No outcome recorded |
| Phase 2/3 | NCT02494973 | May 2015 → Mar 2024 | colorectal cancer | Gustave Roussy, Cancer Campus, Grand Paris | Completed | No outcome recorded |
| Phase 2/3 | NCT02172976 | Nov 2014 → Jan 2020 | pancreatic exocrine neoplasm | Krankenhaus Nordwest | Completed | No outcome recorded |
| Phase 2/3 | NCT02311439 | Oct 2014 → Nov 2016 | malignant pancreatic neoplasm | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02193594 | Jan 2014 → Sep 2017 | gastroesophageal junction adenocarcinoma | Peking University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01787539 | Feb 2013 → Feb 2017 | gastric cancer | Medical University of Lublin | Unknown | No outcome recorded |
| Phase 2/3 | NCT01515787 | Jun 2012 → Dec 2022 | colorectal cancer | Alliance for Clinical Trials in Oncology | Unknown | Met primary |
| Phase 2/3 | NCT01216644 | Aug 2010 → Mar 2017 | gastric cancer | Krankenhaus Nordwest | Completed | Met primary |
| Phase 2/3 | NCT01097265 | Jul 2010 → Jan 2015 | colorectal cancer | Jeroen Bosch Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT01211210 | Jun 2010 → Jun 2017 | rectal cancer | Sun Yat-sen University | Unknown | Missed primary |
| Phase 2/3 | NCT01064999 | Mar 2010 → Mar 2012 | rectal cancer | Fudan University | Unknown | Missed primary |
| Phase 2/3 | NCT01924819 | Sep 2009 → Dec 2026 expected | gastric cancer | Australasian Gastro-Intestinal Trials Group | Active not recruiting | Missed primary |
| Phase 2/3 | NCT00975897 | Jul 2009 → Aug 2010 | colorectal cancer | Medical Research Council | Completed | No outcome recorded |
| Phase 2/3 | NCT00735241 | Jul 2008 → Mar 2009 | colorectal carcinoma, metastasis from malignant tumor of colon | Sirtex Medical | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT00647530 | May 2008 → Dec 2016 | colorectal cancer | University of Birmingham | Unknown | Met primary |
| Phase 2/3 | NCT00861094 | Mar 2008 → Sep 2011 | esophageal cancer | UNICANCER | Completed | Missed primary |
| Phase 2/3 | NCT00304135 | Oct 2005 → Dec 2012 | extrahepatic bile duct carcinoma, gallbladder cancer | Federation Francophone de Cancerologie Digestive | Completed | No outcome recorded |
| Phase 2/3 | NCT00227617 | Jun 2005 → Jan 2012 | carcinoid tumor, digestive system neuroendocrine neoplasm, lung cancer, neoplastic syndrome | University of California, San Francisco | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT00112658 | Nov 2004 → Jun 2010 | pancreatic adenocarcinoma | UNICANCER | Completed | Met primary |
| Phase 2/3 | NCT00208260 | Apr 2004 → Aug 2007 | metastasis from malignant tumor of colon | Institut du Cancer de Montpellier - Val d'Aurelle | Completed | No outcome recorded |
| Phase 2/3 | NCT01196260 | Jan 2004 → Dec 2020 | colorectal cancer | State Key Laboratory of Cancer Biology | Unknown | No outcome recorded |
| Phase 2/3 | NCT00274872 | Jan 2004 → ? | colorectal cancer | GERCOR - Multidisciplinary Oncology Cooperative Group | Unknown | Met primary |
| Phase 3209 trials · 27 met primary · 31 missed | ||||||
| Phase 3 | NCT07584135 | May 2026 → Jan 2029 expected | gastric adenocarcinoma | NingBo Junyan Hongshi Biosciences Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT06783491 | May 2026 → Jun 2030 expected | colorectal carcinoma | Maimónides Biomedical Research Institute of Córdoba | Recruiting | No outcome recorded |
| Phase 3 | NCT07277842 | Dec 2025 → Dec 2028 expected | rectum adenocarcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07366528 | Dec 2025 → Oct 2028 expected | gastric cancer | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07118800 | Dec 2025 → Dec 2030 expected | rectum adenocarcinoma | UNICANCER | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06346197 | Dec 2025 → May 2028 expected | gastric cancer, metastatic malignant neoplasm | Centre Leon Berard | Recruiting | No outcome recorded |
| Phase 3 | NCT07238283 | Dec 2025 → Oct 2028 expected | — | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07235930 | Nov 2025 → Jul 2029 expected | exocrine pancreatic carcinoma | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07267806 | Oct 2025 → Oct 2029 expected | chemotherapy-induced toxicity, hepatocellular carcinoma | Linhui Peng | Recruiting | No outcome recorded |
| Phase 3 | NCT07188025 | Oct 2025 → Oct 2030 expected | rectal cancer | Erasmus Medical Center | Recruiting | No outcome recorded |
| Show all 209 trials opens the full record — a long page | ||||||
| Phase 425 trials · 1 met primary | ||||||
| Phase 4 | NCT07801027 | Nov 2026 → Jan 2030 expected | biliary tract cancer, gastric neoplasm, gastroesophageal junction adenocarcinoma, uterine cervix neoplasm | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07790445 | Jul 2026 → Dec 2028 expected | biliary tract cancer | Zhai Wenlong | Recruiting | No outcome recorded |
| Phase 4 | NCT07446465 | Mar 2026 → Jan 2027 expected | colorectal cancer | Ye Xu | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06931808 | Mar 2025 → Mar 2026 overdue | rectum adenocarcinoma | First Affiliated Hospital of Ningbo University | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06550453 | Sep 2024 → Jan 2025 overdue | colorectal carcinoma | yangjianjun | Recruiting | No outcome recorded |
| Phase 4 | NCT06417606 | May 2024 → Apr 2025 | intrahepatic cholangiocarcinoma | Zhiyong Huang | Unknown | No outcome recorded |
| Phase 4 | NCT06311916 | May 2024 → Dec 2027 expected | hepatocellular carcinoma | Chen Xiaoping | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06311942 | Apr 2024 → Dec 2027 expected | hepatocellular carcinoma | Chen Xiaoping | Recruiting | No outcome recorded |
| Phase 4 | NCT05634720 | Jan 2024 → Nov 2025 overdue | pancreatic ductal adenocarcinoma | Duke University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05203172 | Jul 2022 → Jul 2029 expected | cancer | Pfizer | Recruiting | No outcome recorded |
| Phase 4 | NCT04747951 | Oct 2020 → Oct 2023 | rectal cancer | State Scientific Centre of Coloproctology, Russian Federation | Unknown | No outcome recorded |
| Phase 4 | NCT02557490 | Jan 2015 → Dec 2016 | metastasis from malignant tumor of colon | Zhu Xu | Unknown | No outcome recorded |
| Phase 4 | NCT02557503 | Jan 2015 → Dec 2016 | liver cancer | Zhu Xu | Unknown | No outcome recorded |
| Phase 4 | NCT01959061 | Sep 2013 → Dec 2017 | colorectal cancer | Nanjing Chia-tai Tianqing Pharmaceutical | Unknown | No outcome recorded |
| Phase 4 | NCT02380131 | Feb 2013 → Dec 2017 | gastroesophageal adenocarcinoma | Hebei Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT02284529 | Oct 2012 → Aug 2014 | colorectal cancer | Sinphar Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT01023633 | Oct 2009 → Jan 2014 | colorectal cancer | Nanjing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT01972503 | Jun 2008 → Sep 2013 | colorectal cancer, hepatobiliary neoplasm, metastatic neoplasm | Xu jianmin | Unknown | Met primary |
| Phase 4 | NCT00577031 | Feb 2008 → Aug 2011 | colorectal cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00874406 | Jan 2008 → Dec 2009 | colorectal cancer | Fudan University | Unknown | No outcome recorded |
| Phase 4 | NCT00274885 | Oct 2005 → ? | cancer | GERCOR - Multidisciplinary Oncology Cooperative Group | Unknown | No outcome recorded |
| Phase 4 | NCT00559676 | Mar 2005 → May 2011 | colorectal cancer | Centre Hospital Regional Universitaire de Limoges | Completed | No outcome recorded |
| Phase 4 | NCT00129870 | Feb 2005 → Dec 2007 | colorectal cancer | Sanofi | Terminated | No outcome recorded |
| Phase 4 | NCT00868816 | Jan 2005 → Dec 2007 | colorectal cancer | Fudan University | Completed | No outcome recorded |
| Phase 4 | NCT00263055 | Aug 2004 → Jun 2005 | colonic neoplasm | Sanofi | Completed | No outcome recorded |
| Phase not applicable69 trials · 1 met primary · 2 missed | ||||||
| — | NCT07854964 | Oct 2026 → May 2030 expected | — | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07859410 | Oct 2026 → Oct 2028 expected | gastroesophageal junction adenocarcinoma | Anhui Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07613905 | Sep 2026 → Dec 2028 expected | hypersensitivity reaction disease | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07542912 | Jun 2026 → Jun 2029 expected | — | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| — | NCT07855757 | Jun 2026 → Jun 2028 expected | gastric cancer, peritoneal carcinomatosis | Zhejiang Cancer Hospital | Active not recruiting | No outcome recorded |
| — | NCT07618546 | May 2026 → Mar 2027 expected | hepatocellular carcinoma | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07283939 | Feb 2026 → May 2030 expected | appendix carcinoma, cancer of unknown primary site, carcinoma of esophagus, carcinoma of the ampulla of vater +3 | Alliance for Clinical Trials in Oncology | Recruiting | No outcome recorded |
| — | NCT07474103 | Nov 2025 → Mar 2028 expected | rectum adenocarcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| — | NCT07334587 | Sep 2025 → Feb 2026 overdue | colorectal carcinoma | Allama Iqbal Medical College | Enrolling by invitation | No outcome recorded |
| — | NCT06893887 | May 2025 → Dec 2027 expected | hepatocellular carcinoma | Nanjing Tianyinshan Hospital | Recruiting | No outcome recorded |
| — | NCT06894797 | Apr 2025 → Oct 2026 expected | — | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
| — | NCT06688786 | Nov 2024 → Jul 2025 overdue | rectal cancer | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Active not recruiting | No outcome recorded |
| — | NCT06831981 | Sep 2024 → Jun 2036 expected | rectal cancer | University Hospital Tuebingen | Recruiting | No outcome recorded |
| — | NCT06519578 | Aug 2024 → Jul 2026 overdue | hepatocellular carcinoma | RenJi Hospital | Recruiting | No outcome recorded |
| — | NCT06313554 | May 2024 overdue | intrahepatic cholangiocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| — | NCT06494514 | Apr 2024 → Apr 2027 expected | pancreatic exocrine neoplasm | Du Juan | Recruiting | No outcome recorded |
| — | NCT06052332 | Feb 2024 → Dec 2029 expected | — | Jules Bordet Institute | Recruiting | No outcome recorded |
| — | NCT06199232 | Jan 2024 → Jun 2026 overdue | metastasis from malignant tumor of colon | Peking University | Active not recruiting | No outcome recorded |
| — | NCT06158919 | Nov 2023 → Nov 2024 overdue | gastroesophageal junction adenocarcinoma | Fudan University | Recruiting | No outcome recorded |
| — | NCT06035133 | Nov 2023 → Nov 2024 overdue | rectal cancer | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06157216 | Oct 2023 → Apr 2027 expected | gastric cancer | Qilu Hospital of Shandong University | Active not recruiting | No outcome recorded |
| — | NCT05928312 | Aug 2023 → Jun 2025 | colorectal cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| — | NCT05877573 | Jul 2023 → Jan 2025 overdue | rectal cancer | Nanfang Hospital, Southern Medical University | Recruiting | No outcome recorded |
| — | NCT05705687 | May 2023 → Feb 2031 expected | nongerminomatous germ cell tumor | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| — | NCT05832398 | May 2023 → Jan 2025 | colorectal cancer | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| — | NCT05644249 | Dec 2022 → Jun 2025 | gastric cancer, peritoneal carcinomatosis | Vilnius University | Completed | No outcome recorded |
| — | NCT05621499 | Nov 2022 → Nov 2023 | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT05718492 | Oct 2022 → Oct 2025 overdue | hepatocellular carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT06048146 | Oct 2022 → Sep 2025 | metastatic malignant neoplasm in the lymph nodes, rectal cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| — | NCT05496491 | Aug 2022 → Aug 2026 overdue | rectal cancer | Larissa University Hospital | Recruiting | No outcome recorded |
| — | NCT05385900 | Jun 2022 → Jun 2023 | gastric cancer | Xijing Hospital | Unknown | No outcome recorded |
| — | NCT06495463 | Mar 2022 → Dec 2024 | colorectal cancer | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT05978349 | Feb 2022 → Sep 2025 | colorectal cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT04842006 | Dec 2021 → Aug 2028 expected | colorectal cancer | Helsinki University Central Hospital | Recruiting | No outcome recorded |
| — | NCT05050760 | Sep 2021 → Dec 2023 | esophageal squamous cell carcinoma | Xijing Hospital | Unknown | No outcome recorded |
| — | NCT05424692 | Sep 2021 → Sep 2025 overdue | chemotherapy-induced toxicity, colon carcinoma, rectal carcinoma | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| — | NCT05000697 | Jul 2021 → Apr 2027 expected | rectal cancer | Hospital Alemão Oswaldo Cruz | Recruiting | No outcome recorded |
| — | NCT04891900 | May 2021 → Dec 2024 | gastric cancer, gastroesophageal junction adenocarcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| — | NCT04886193 | Apr 2021 → May 2022 | gastric cancer | Guangdong Provincial Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT04521491 | Dec 2020 → Dec 2022 | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Unknown | No outcome recorded |
| — | NCT03904043 | Jul 2020 → Aug 2024 | rectum adenocarcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT04198051 | Dec 2019 → Dec 2020 | colon carcinoma, gastric cancer | The First Affiliated Hospital of Dalian Medical University | Unknown | No outcome recorded |
| — | NCT04174339 | Dec 2019 → Dec 2020 | gastric adenocarcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| — | NCT04047953 | Sep 2019 → Dec 2023 overdue | gastric adenocarcinoma | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
| — | NCT03217097 | Oct 2018 → Jan 2022 | neuroendocrine neoplasm | Hospices Civils de Lyon | Completed | Missed primary |
| — | NCT03398512 | Feb 2018 → Mar 2020 | peritoneal carcinomatosis | Wuhan University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT03349827 | Jan 2018 → Mar 2020 | peritoneal carcinomatosis | Wuhan University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT03413514 | Jan 2018 → Jan 2019 | gastric cancer | Peking University | Unknown | No outcome recorded |
| — | NCT03071198 | Mar 2017 → Sep 2018 | rectal cancer | Harbin Medical University | Unknown | No outcome recorded |
| — | NCT03045770 | Feb 2017 → Dec 2019 | gastroesophageal junction adenocarcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| — | NCT03042000 | Feb 2017 → Dec 2020 | rectum adenocarcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT02813096 | Oct 2016 → Jul 2018 | hepatocellular carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
| — | NCT02569723 | Oct 2015 → Apr 2018 | colon adenocarcinoma | Edward Kim | Completed | No outcome recorded |
| — | NCT02358863 | Feb 2015 → Nov 2016 | esophageal cancer, gastric cancer | Georgetown University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01792934 | May 2013 → Jan 2025 overdue | colorectal cancer | Radboud University Medical Center | Active not recruiting | Missed primary |
| — | NCT01771146 | Oct 2012 → Sep 2017 | malignant pancreatic neoplasm | Baylor Research Institute | Unknown | No outcome recorded |
| — | NCT01364376 | Jun 2011 → Aug 2016 | gastric neoplasm | Zhejiang University | Completed | Met primary |
| — | NCT01295086 | Mar 2011 → Nov 2014 | adenocarcinoma | Odense University Hospital | Completed | No outcome recorded |
| — | NCT01280643 | Mar 2010 → Jul 2013 | colorectal cancer | Fox Chase Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00994864 | Nov 2009 → Dec 2022 | colon carcinoma | Jules Bordet Institute | Completed | No outcome recorded |
| — | NCT01366118 | Oct 2009 → Apr 2011 | rectal carcinoma | Grupo Hospital de Madrid | Completed | No outcome recorded |
| — | NCT00826800 | Feb 2009 → Jan 2011 | colon carcinoma | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00462501 | Mar 2007 → Feb 2014 | colorectal cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT00430027 | Nov 2006 → Aug 2008 | esophageal adenocarcinoma | University of Colorado, Denver | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00415298 | May 2006 → ? | head and neck cancer | University of California, San Diego | Unknown | No outcome recorded |
| — | NCT00448838 | May 2006 → Aug 2007 | malignant pancreatic neoplasm | University of Miami | Completed | No outcome recorded |
| — | NCT00250029 | Apr 2004 → Sep 2005 | cancer, colonic disorder | New Mexico Cancer Research Alliance | Completed | No outcome recorded |
| — | NCT00039611 | May 2002 → Oct 2007 | colorectal cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| — | NCT00040820 | Jan 2002 → Aug 2003 | colorectal cancer | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase not stated3 trials · 1 met primary | ||||||
| — | NCT02436044 | — | hepatic vascular disorder, hepatocellular carcinoma | Ming Zhao | Approved for marketing | No outcome recorded |
| — | NCT01216124 | — | triple-negative breast carcinoma | Fudan University | Available | No outcome recorded |
| — | NCT00786058 | — | malignant pancreatic neoplasm | CONKO-Studiengruppe | Approved for marketing | Met primary |
| Comparator or background therapy1,126 trials | ||||||
| Phase 0 | NCT07328087 Background | Feb 2026 → Dec 2030 expected | colorectal cancer | Biogenea Pharmaceuticals Ltd. | Recruiting | No outcome recorded |
| Phase 0 | NCT07167446 Background | Oct 2025 → Sep 2027 expected | chemotherapy-induced neuropathy, colorectal cancer | Fox Chase Cancer Center | Recruiting | No outcome recorded |
| Phase 0 | NCT07034742 Background | Jun 2025 → Jan 2026 overdue | gastric adenocarcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 0 | NCT06525714 Background | Aug 2024 → Jul 2029 expected | gastric cancer | The First Hospital of Jilin University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06011772 Background | Dec 2023 → Feb 2026 overdue | colorectal cancer | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Show all 1,126 trials opens the full record — a long page | ||||||
Press releases naming this drug 16 releases
Evidence & citations 34 cited values
Every value below carries the sentence it was read from. 2,881 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | oxaliplatin | “Adjuvant chemotherapy: FOLFOX6 regiment : Oxaliplatin（Hengrui Medicine Co., Ltd，China） 85mg/m2 IV d1, Leucovorin （Hengrui Medicine Co., Ltd，China）400mg/m2 IV d1, 5-FU（Hengrui...” NCT01889303 ↗2858“Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to...” NCT05959356 ↗ “Oxaliplatin will be administered intravenously at a dose of 100 mg/m\^2 along with folinic acid administration intravenously at a dose of 400 mg/m\^2 (racemic) or 200 mg/m\^2...” NCT00778830 ↗ “After 24 weeks of induction therapy with either fluorouracil plus leucovorin plus oxaliplatin or capecitabine plus oxaliplatin, both with bevacizumab, patients without disease...” PMID 26361971 ↗ Sep 2015 “The dosing regimen during the dose escalation phase will include three different doses of fruquintinib (3 mg, 4 mg and 5 mg, per oral, once per day days 1-14) + sintilimab,...” PMID 41005780 ↗ Sep 2025 “After achieving objective tumor response or stable disease after 3 cycles of capecitabine and oxaliplatin or 4 cycles of 5-fluorouracil and oxaliplatin with or without...” PMID 41837962 ↗ Apr 2026 “Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2...” NCT02527772 ↗ “The neoadjuvant treatment regimen will consist of Oxaliplatin at a dose of 130mg/m2, administered intravenously over a period of more than 2 hours on Day 1, every 3 weeks; and...” NCT06014372 ↗ “Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for...” NCT05290116 ↗ “patients with locally advanced or metastatic BTC and an Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned (1:1) to receive oxaliplatin,...” PMID 34662180 ↗ Oct 2021 “Oxaliplatin 85 mg/m2 IV, folinic acid 400 mg/m2 IV (or L-folinic acid 200 mg/m²), and fluorouracil (5-FU) 400 mg/m² IV bolus; followed by 5 FU 2400 mg/m2 as a 46 hour...” NCT06846346 ↗ |
| Known as | 205803BIJ | “OXALIPLATIN (205803BIJ)” NCT02191566 ↗ |
| Known as | diaminocyclohexane-platinum | “Oxaliplatin, diaminocyclohexane-platinum, is an alkylating agent inhibiting DNA replication” NCT00786006 ↗ |
| Known as | Eloxatin | “Oxaliplatin(Eloxatin®) + 5-FU/LV (FOLFOX4) Compared With Single Agent Doxorubicin (Adriamycin®) as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients...” NCT00471965 ↗33“A Phase II Study of Oxaliplatin (Eloxatin) Capecitabine (Xeloda) and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer.” NCT00220051 ↗ “Phase I Study of Oxaliplatin (Eloxatin) and Capecitabine (Xeloda) and Concurrent Radiation Therapy (XELOX-RT) in Non-Small Cell Lung Cancer” NCT00268151 ↗ “a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.” NCT02723253 ↗ “based on 5-fluorouracil, folinic acid, and oxaliplatin (Eloxatin®), with the EGF receptor antibody cetuximab (Erbitux®)” NCT00145314 ↗ “OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis” NCT05262452 ↗ “oral Xeloda with intravenous (IV) Eloxatin (oxaliplatin) and IV bevacizumab (Avastin) as a first-line treatment” NCT00118755 ↗ “the combination of the chemotherapeutic agents capecitabine (Xeloda) and oxaliplatin (Eloxatin)” NCT00394992 ↗ “Oxaliplatin (Eloxatin) at 65 mg/m2 given as a 2-hr IV infusion via a central venous port” NCT03374852 ↗ “Eloxatin (oxaliplatin), leucovorin (folinic acid) and 5-Fluorouracil (5-FU)” NCT00265850 ↗ “Oxaliplatin (Eloxatin), 5FU (5-Fluorouracil) and Leucovorin (Folinic Acid)” NCT00580073 ↗ |
| Known as | Eloxatin (oxaliplatin) | “Eloxatin (oxaliplatin)” NCT00517829 ↗ |
| Known as | Eloxatinâ | “Phase II Study of the A-ICOX Regimen Consisting of Bevacizumab (Avastinâ), Intermittent Dose Capecitabine (Xelodaâ) and Oxaliplatin (Eloxatinâ) in Patients With Untreated...” NCT00177307 ↗ |
| Known as | JM-83 | ChEMBL registry synonym — accepted as the source's own label CHEMBL414804 ↗ |
| Known as | l-OHP | “The treatment schedule comprised S-1 40-60 mg bid and leucovorin (LV) 25 mg bid for one week and 2 hour drip infusion of oxaliplatin (L-OHP) 85 mg/m2 on day 1, 1 week off,...” PMID 26158159 ↗ Jun 20148“To determine the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of docetaxel in combination with oxaliplatin (L-OHP) as first-line treatment” PMID 12680184 ↗ Jan 2003 “Meanwhile, oxaliplatin (l-OHP), an alkylating diaminocyclohexane platinum derivate, has been noted to display a marked cytotoxic synergism” NCT01470443 ↗ “Oxaliplatin (L-OHP) 130 mg/m², IV infusion over 2 hours on Day 1” NCT07268677 ↗ “Oxaliplatin (L-OHP)” NCT02497157 ↗ “L-OHP” NCT01212822 ↗ |
| Known as | LIOX | “5 - 7 LIOX (liver isolation oxaliplatin) intra-arterial infusions over 8 weeks + capecitabine” NCT04701281 ↗ |
| Known as | MBP-426 (LIPOSOMAL OXALIPLATIN) | ChEMBL registry synonym — accepted as the source's own label CHEMBL414804 ↗ |
| Known as | NSC 266046 | “Oxaliplatin (NSC 266046) in Combination With 5-Fluorouracil and Leucovorin (FOLFOX4) for Patients Who Have Not Received Prior Chemotherapy for Advanced Colorectal Cancer” NCT00039611 ↗1“Oxaliplatin (NSC 266046)” NCT00058149 ↗ |
| Known as | OHP | “using oxaliplatin (OHP) and endostatin in patients with inoperable esophageal squamous cell carcinoma (ESCC).” PMID 30850562 ↗ Mar 20191“using paclitaxel (PTX) plus oxaliplatin (OHP)” NCT02607982 ↗ |
| Known as | Orectalip | “Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer” NCT02284529 ↗ |
| Known as | OXA | “Oxaliplatin (OXA), a third-generation platinum-based anticancer drug, has better efficacy and lower toxicity than cisplatin and carboplatin.” NCT06856447 ↗10“Clinical activity of several regimens containing oxaliplatin (OXA) in advanced HCC had been demonstrated in phase II studies.” NCT02452853 ↗ “Clinical activity of several regimens containing oxaliplatin (OXA) in advanced HCC had been demonstrated in phase II studies.” NCT02426450 ↗ “For grade I-III hypersensitivity to oxaliplatin, oxa 0.01 mg/ml, 0.1 mg/ml and 5 mg/ml were used in sequence for skin test.” NCT05922358 ↗ “Patients are planned to receive the SIRIOX regimen including Oxaliplatin (OXA, 85 mg/m2; d1,d15) of every cycle.” NCT03403101 ↗ “oxaliplatin (OXA) 120 mg/sm, cisplatin (CDDP) 10.5 mg/sm and doxorubicin (DXR) 2.1 mg/sm.” PMID 34070561 ↗ May 2021 “Oxaliplatin (OXA) : 130mg/m2, intravenous infusion, d1, infusion more than 2 hours.” NCT04792515 ↗ “FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).” NCT04521491 ↗ “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab” NCT02337946 ↗ “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab” NCT02394795 ↗ “Intraperitoneal (IP) OXAliplatin (OXA)” NCT02866903 ↗ |
| Known as | OXAL | “A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic...” NCT00056030 ↗4“A Phase II Study of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), and Leucovorin (CF) in Patients With Metastatic Colorectal Carcinoma Previously Treated With Irinotecan (CPT-11)” NCT00016978 ↗ “In vitro synergy between Oxal (oxaliplatin) and CPT-11 (irinotecan) has been reported.” PMID 12196376 ↗ Sep 2002 “systemic oxaliplatin (Oxal) combinations plus hepatic arterial infusion (HAI)” PMID 16009951 ↗ Jul 2005 “Drug: Oxaliplatin (OXAL)” NCT02008656 ↗ |
| Known as | Oxali | “The drugs that will be given by vein are OXALIPLATIN ("Oxali") plus 5-FLUOROURACIL and LEUCOVORIN ("5FU" and "LV").” NCT00059930 ↗ |
| Known as | Oxaliplatin (Eloxatin) | “Oxaliplatin (Eloxatin)” NCT02178709 ↗7“Oxaliplatin (Eloxatin)” NCT01516216 ↗ “Oxaliplatin (Eloxatin)” NCT00659269 ↗ “Oxaliplatin (Eloxatin)” NCT01571024 ↗ “Oxaliplatin (Eloxatin)” NCT00923637 ↗ “Oxaliplatin (Eloxatin)” NCT01749956 ↗ “Oxaliplatin: Eloxatin” NCT01932580 ↗ “Oxaliplatin: Eloxatin” NCT00463840 ↗ |
| Known as | Oxaliplatin (Eloxatin○R, company: Sanofi-Avantis | “Oxaliplatin (Eloxatin○R, company: Sanofi-Avantis” NCT01558011 ↗ |
| Known as | Oxaliplatin (L-OHP, Eloxatin, Sanofi-Synthelabo) | “Oxaliplatin (L-OHP, Eloxatin®, Sanofi-Synthelabo)” NCT00153998 ↗ |
| Known as | oxaliplatin (ox) | “oxaliplatin (ox)” NCT04617457 ↗ |
| Known as | oxaliplatin (Oxalip, TTY Biopharm, TW) | “oxaliplatin (Oxalip, TTY Biopharm, TW)” NCT04999332 ↗ |
| Known as | Oxaliplatin Accord | “Oxaliplatin (chemical name: L01XA03; trade name: Oxaliplatin Accord; formulation: concentrate for solution for injection)” NCT07472868 ↗ |
| Known as | Oxaliplatin component of folfox | ChEMBL registry synonym — accepted as the source's own label CHEMBL414804 ↗ |
| Known as | Oxaliplatin component of xelox | ChEMBL registry synonym — accepted as the source's own label CHEMBL414804 ↗ |
| Known as | Oxaliplatin injection | “Drug: Oxaliplatin injection” NCT05799820 ↗ |
| Known as | oxaliplatine | “capecitabine 625 mg/m2 twice daily on days 1-7 oxaliplatine 85 mg/m2 on Day 1 irinotecan 90 mg/m2 on Day 3, every 14 days” NCT03974854 ↗14“FOLFOX 4 : Oxaliplatine : 85 mg/m² 2h continuous perfusion during levorin d1 every 2weeks” NCT00208260 ↗ “Oxaliplatine : 85 mg/m² inG5% orNaCl 0.9% in IV (D1) during 2 hours” NCT03584711 ↗ “Oxaliplatine 85 mg/m² IV infusion on D1” NCT04736485 ↗ “oxaliplatine 85mg/m2、ivdrip，d1，q3w” NCT05101616 ↗ “Capecitabine + Oxaliplatine” NCT05912075 ↗ |
| Known as | Oxaliplatino | “XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks” NCT00335595 ↗ |
| Known as | Oxalitin | “S-1 (TS-1) and Oxaliplatin (Oxalitin)” NCT00961077 ↗ |
| Known as | RP-54780 | ChEMBL registry synonym — accepted as the source's own label CHEMBL414804 ↗ |
| Known as | SR96669 | “Drug: oxaliplatin (SR96669)” NCT01245582 ↗4“Oxaliplatin (SR96669)” NCT00275210 ↗ “Oxaliplatin (SR96669)” NCT01515748 ↗ “OXALIPLATIN (SR96669)” NCT00988897 ↗ “Oxaliplatin (SR96669)” NCT00094965 ↗ |
| Known as | Xaliplatin | ChEMBL registry synonym — accepted as the source's own label CHEMBL414804 ↗ |
| Action | Inhibit | “Drugs used in chemotherapy, such as oxaliplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.” NCT00217581 ↗ |
| Modality | Small molecule | “Oxaliplatin, a platinum-based chemotherapeutic agent” PMID 14981738 ↗ Mar 2004 |
| Route | Intravenous | “130 mg/m(2) given intravenously over 2 hours every 3 weeks” NCT00001835 ↗ |